Recent advances in molecular mechanisms of NSCLC lead to successful development of several generations of small molecule drugs specifically targeting certain genetic mutations of coding genes 9, 10, such as EGFR, HER2, ALK, KRAS, BRAF. Despite these progressions, the five-year survival rate for NSCLC remains low. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.